X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (155) 155
humans (137) 137
male (116) 116
female (115) 115
middle aged (110) 110
hepatitis c, chronic - drug therapy (97) 97
adult (96) 96
gastroenterology & hepatology (85) 85
hepatitis c (83) 83
hepacivirus - genetics (81) 81
ribavirin (77) 77
genotype (72) 72
drug therapy, combination (71) 71
hepatitis c virus (68) 68
aged (66) 66
gastroenterology and hepatology (66) 66
antiviral agents - therapeutic use (64) 64
treatment outcome (60) 60
hepatitis (51) 51
hepatitis c, chronic - virology (50) 50
interferon (50) 50
antiviral agents - administration & dosage (49) 49
antiviral agents - adverse effects (49) 49
care and treatment (47) 47
sofosbuvir (47) 47
abridged index medicus (45) 45
ribavirin - therapeutic use (41) 41
antiviral agents (40) 40
ribavirin - administration & dosage (38) 38
young adult (38) 38
health aspects (37) 37
hepacivirus - drug effects (37) 37
cirrhosis (34) 34
double-blind method (34) 34
viral nonstructural proteins - antagonists & inhibitors (34) 34
clinical trials (33) 33
genetic aspects (33) 33
plus ribavirin (33) 33
telaprevir (33) 33
drug therapy (32) 32
infections (31) 31
patients (31) 31
therapy (31) 31
genotype & phenotype (30) 30
pharmacology & pharmacy (30) 30
polyethylene glycols - therapeutic use (29) 29
interferon-alpha - therapeutic use (28) 28
genotypes (27) 27
interferon-alpha - administration & dosage (27) 27
liver cirrhosis (27) 27
hcv (26) 26
medicine, general & internal (26) 26
rna, viral - blood (26) 26
biological response modifiers (25) 25
polyethylene glycols - administration & dosage (25) 25
ribavirin - adverse effects (25) 25
uridine monophosphate - analogs & derivatives (25) 25
viral load (25) 25
boceprevir (24) 24
hepatitis c - drug therapy (24) 24
adolescent (23) 23
liver diseases (23) 23
virus diseases (23) 23
chronic hepatitis-c (21) 21
fibrosis (21) 21
liver (21) 21
recombinant proteins - therapeutic use (21) 21
analysis (20) 20
infection (20) 20
infectious diseases (20) 20
recombinant proteins - administration & dosage (20) 20
chronic infection (19) 19
interferon-alpha - adverse effects (19) 19
medical research (19) 19
polyethylene glycols - adverse effects (19) 19
proteases (19) 19
virology (19) 19
drug administration schedule (18) 18
drug resistance, viral (18) 18
protease inhibitors (18) 18
combination (17) 17
dose-response relationship, drug (17) 17
hepatitis c, chronic - complications (17) 17
medicine, experimental (17) 17
microbiology (17) 17
virus-infection (17) 17
hepacivirus - classification (16) 16
combination therapy (15) 15
sustained virologic response (15) 15
uridine monophosphate - therapeutic use (15) 15
viruses (15) 15
antiviral agents - pharmacokinetics (14) 14
dosage and administration (14) 14
genotype 1 (14) 14
hepacivirus - isolation & purification (14) 14
recombinant proteins - adverse effects (14) 14
sustained virological response (14) 14
hepatitis c, chronic - genetics (13) 13
in-vitro (13) 13
replication (13) 13
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 15, pp. 1448 - 1455
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 27, pp. 2608 - 2617
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 27, pp. 2618 - 2628
Journal Article
Gut, ISSN 0017-5749, 06/2015, Volume 64, Issue 6, pp. 948 - 956
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9956, pp. 1756 - 1765
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9742, pp. 705 - 716
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2013, Volume 368, Issue 18, pp. 1685 - 1694
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2013, Volume 368, Issue 20, pp. 1867 - 1877
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 16, pp. 1483 - 1493
In this study in patients with HCV genotype 1 infection and prior treatment failure, those assigned to 12 weeks or 24 weeks of treatment with ledipasvir and... 
NS5A INHIBITOR | MEDICINE, GENERAL & INTERNAL | TREATMENT-NAIVE | C VIRUS-INFECTION | RIBAVIRIN | HEPATITIS-C |